Journal Mobile Options
Table of Contents
Vol. 24, No. 5, 2007
Issue release date: October 2007
Dement Geriatr Cogn Disord 2007;24:389–395

Increased Saliva Cortisol Awakening Response in Patients with Mild Cognitive Impairment

Lind K. · Edman Å. · Nordlund A. · Olsson T. · Wallin A.
aInstitute of Neuroscience and Physiology, Sahlgrenska Academy, Göteborg University, Mölndal, and bDepartment of Public Health and Clinical Medicine, Umeå University Hospital, Umeå, Sweden

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: It is unknown whether HPA-axis dysfunction is present in patients with mild cognitive impairment (MCI). The aim of the present study was to investigate whether cortisol levels are elevated among patients with MCI and/or whether the individuals have adequate feedback control of their HPA axis. Material and Methods: 27 patients with MCI and 15 healthy controls were included in the study. Saliva samplings were performed 5 times a day before intake of 0.5 mg dexamethasone, and 5 times a day after intake of dexamethasone, respectively. Results: Significantly higher cortisol levels were found 15 min after awakening among patients with MCI in comparison with the controls, both before and after dexamethasone administration (p < 0.05). Also, the ratio between cortisol at awakening time and 15 min after awakening was lower in the patient group after dexamethasone administration (p < 0.05). There were no significant differences in basal cortisol levels before or after dexamethasone between groups. Conclusion: The results indicate that there is an HPA-axis disturbance, with normal basal cortisol levels and increased awakening response among patients with MCI. The dissociation between basal values and the awakening response may be of pathophysiological importance for the cognitive impairment.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  2. Ritchie K, Artero S, Touchon J: Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001;56:37–42.
  3. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M: Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol 2000;57:675–680.
  4. Luis CA, Barker WW, Loewenstein DA, Crum TA, Rogaeva E, Kawarai T, St George-Hyslop P, Duara R: Conversion to dementia among two groups with cognitive impairment: a preliminary report. Dement Geriatr Cogn Disord 2004;18:307–313.
  5. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC: Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240–246.
  6. Frisoni GB, Galluzzi S, Bresciani L, Zanetti O, Geroldi C: Mild cognitive impairment with subcortical vascular features: clinical characteristics and outcome. J Neurol 2002;249:1423–1432.
  7. Meyer JS, Xu G, Thornby J, Chowdhury MH, Quach M: Is mild cognitive impairment prodromal for vascular dementia like Alzheimer’s disease? Stroke 2002;33:1981–1985.
  8. Convit A, De Leon MJ, Tarshish C, De Santi S, Tsui W, Rusinek H, George A: Specific hippocampal volume reductions in individuals at risk for Alzheimer’s disease. Neurobiol Aging 1997;18:131–138.
  9. Jack CR Jr, Petersen RC, Xu YC, Waring SC, O’Brien PC, Tangalos EG, Smith GE, Ivnik RJ, Kokmen E: Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 1997;49:786–794.
  10. De Santi S, de Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A, Tsui WH, Kandil E, Boppana M, Daisley K, Wang GJ, Schlyer D, Fowler J: Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529–539.
  11. Jacobson L, Sapolsky R: The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 1991;12:118–134.
  12. Wolf OT, Convit A, Thorn E, de Leon MJ: Salivary cortisol day profiles in elderly with mild cognitive impairment. Psychoneuroendocrinology 2002;27:777–789.
  13. Hatzinger M, Z’Brun A, Hemmeter U, Seifritz E, Baumann F, Holsboer-Trachsler E, Heuser IJ: Hypothalamic-pituitary-adrenal system function in patients with Alzheimer’s disease. Neurobiol Aging 1995;16:205–209.
  14. Umegaki H, Ikari H, Nakahata H, Endo H, Suzuki Y, Ogawa O, Nakamura A, Yamamoto T, Iguchi A: Plasma cortisol levels in elderly female subjects with Alzheimer’s disease: a cross-sectional and longitudinal study. Brain Res 2000;881:241–243.
  15. Giubilei F, Patacchioli FR, Antonini G, Sepe Monti M, Tisei P, Bastianello S, Monnazzi P, Angelucci L: Altered circadian cortisol secretion in Alzheimer’s disease: clinical and neuroradiological aspects. J Neurosci Res 2001;66:262–265.
  16. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser I: Twenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging 1997;18:285–289.
  17. Nasman B, Olsson T, Viitanen M, Carlstrom K: A subtle disturbance in the feedback regulation of the hypothalamic-pituitary-adrenal axis in the early phase of Alzheimer’s disease. Psychoneuroendocrinology 1995;20:211–220.
  18. Gottfries CG, Balldin J, Blennow K, Brane G, Karlsson I, Regland B, Wallin A: Regulation of the hypothalamic-pituitary-adrenal axis in dementia disorders. Ann NY Acad Sci 1994;746:336–343; discussion 343–344.
  19. Rasmuson S, Andrew R, Nasman B, Seckl JR, Walker BR, Olsson T: Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer’s disease. Biol Psychiatry 2001;49:547–552.
  20. Csernanansky JG, Dong H, Fagan AM, Wang L, Xiong C, Holzman DM, Morris JC: Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am J Psychiatry 2006;163:2164–2169.
  21. Swanwick GR, Kirby M, Bruce I, Buggy F, Coen RF, Coakley D, Lawlor BA: Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer’s disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry 1998;155:286–289.
  22. Waltman C, Blackman MR, Chrousos GP, Riemann C, Harman SM: Spontaneous and glucocorticoid-inhibited adrenocorticotropic hormone and cortisol secretion are similar in healthy young and old men. J Clin Endocrinol Metab 1991;73:495–502.
  23. Lupien S, Lecours AR, Schwartz G, Sharma S, Hauger RL, Meaney MJ, Nair NP: Longitudinal study of basal cortisol levels in healthy elderly subjects: evidence for subgroups. Neurobiol Aging 1996;17:95–105.
  24. Dodt C, Theine KJ, Uthgenannt D, Born J, Fehm HL: Basal secretory activity of the hypothalamo-pituitary-adrenocortical axis is enhanced in healthy elderly: an assessment during undisturbed night-time sleep. Eur J Endocrinol 1994;131:443–450.
  25. Van Cauter E, Leproult R, Kupfer DJ: Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol. J Clin Endocrinol Metab 1996;81:2468–2473.
  26. Kern W, Dodt C, Born J, Fehm HL: Changes in cortisol and growth hormone secretion during nocturnal sleep in the course of aging. J Gerontol A Biol Sci Med Sci 1996;51:M3–M9.
  27. Karlamanga AS, Singer BH, Chodosh J, McEwen B, Seeman TE: Urinary cortisol excretion as a predictor of incident cognitive impairment. Neurobiol Aging 2005;26 (suppl 1):80–84.
  28. Nordlund A, Rolstad S, Hellstrom P, Sjogren M, Hansen S, Wallin A: The Goteborg MCI study: mild cognitive impairment is a heterogeneous condition. J Neurol Neurosurg Psychiatry 2005;76:1485–1490.
  29. Wallin A, Edman A, Blennow K, Gottfries CG, Karlsson I, Regland B, Sjogren M: Stepwise comparative status analysis (STEP): a tool for identification of regional brain syndromes in dementia. J Geriatr Psychiatry Neurol 1996;9:185–199.
  30. Royall DR, Mahurin RK, Gray KF: Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc 1992;40:1221–1226.
  31. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  32. Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997;9(suppl 1):173–176; discussion 177–178.
  33. Reisberg B, Ferris SH, de Leon MJ, Crook T: Global Deterioration Scale (GDS). Psychopharmacol Bull 1988;24:661–663.
  34. Good P: Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. New York, Springer, 2000, pp 36–37.
  35. Wust S, Federenko I, Hellhammer DH, Kirschbaum C: Genetic factors, perceived chronic stress, and the free cortisol response to awakening. Psychoneuroendocrinology 2000;25:707–720.
  36. Checkley S: The neuroendocrinology of depression and chronic stress. Br Med Bull 1996;52:597–617.
  37. Pruessner JC, Hellhammer DH, Kirschbaum C: Burnout, perceived stress, and cortisol responses to awakening. Psychosom Med 1999;61:197–204.
  38. Geiss A, Varadi E, Steinbach K, Bauer HW, Anton F: Psychoneuroimmunological correlates of persisting sciatic pain in patients who underwent discectomy. Neurosci Lett 1997;237:65–68.
  39. Roberts AD, Wessely S, Chalder T, Papadopoulos A, Cleare AJ: Salivary cortisol response to awakening in chronic fatigue syndrome. Br J Psychiatry 2004;184:136–141.
  40. Wessa M, Rohleder N, Kirschbaum C, Flor H: Altered cortisol awakening response in posttraumatic stress disorder. Psychoneuroendocrinology 2006;31:209–215.
  41. Yehuda R, Golier JA, Kaufman S: Circadian rhythm of salivary cortisol in Holocaust survivors with and without PTSD. Am J Psychiatry 2005;162:998–1000.
  42. Fisher S, Reason J (eds): Handbook of Life Stress, Cognition and Health. Chichester, Wiley, 1988, p 631.
  43. McEwen BS, Stellar E: Stress and the individual: mechanisms leading to disease. Arch Intern Med 1993;153:2093–2101.
  44. Buchanan TW, Kern S, Allen JS, Tranel D, Kirschbaum C: Circadian regulation of cortisol after hippocampal damage in humans. Biol Psychiatry 2004;56:651–656.
  45. Wolf OT, Fujiwara E, Luwinski G, Kirschbaum C, Markowitsch HJ: No morning cortisol response in patients with severe global amnesia. Psychoneuroendocrinology 2005;30:101–105.
  46. McEwen BS, De Kloet ER, Rostene W: Adrenal steroid receptors and actions in the nervous system. Physiol Rev 1986;66:1121–1188.
  47. De Kloet ER, Oitzl MS, Joels M: Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci 1999;22:422–426.
  48. Herman JP, Cullinan WE: Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 1997;20:78–84.
  49. Tuvnes FA, Steffenach HA, Murison R, Moser MB, Moser EI: Selective hippocampal lesions do not increase adrenocortical activity. J Neurosci 2003;23:4345–4354.
  50. Kishiyama MM, Yontelinas AP, Lazzara MM: The von Restorff effect in amnesia: the contribution of the hippocampal system to novelty-related memory enhancements. J Cogn Neurosci 2004;16:15–23.
  51. Diamond DM, Fleshner M, Ingersoll N, Rose GM: Psychological stress impairs spatial working memory: relevance to electrophysiological studies of hippocampal function. Behav Neurosci 1996;110:661–672.
  52. Oitzl MS, de Kloet ER: Selective antagonists modulate specific aspects of spatial orientation learning. Behav Neurosci 1992;106:62–71.
  53. De Kloet ER, Joels M, Holsboer F: Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005;6:463–475.
  54. Sapolsky RM, Uno H, Rebert CS, Finch CE: Hippocampal damage associated with prolonged glucocorticoid exposure in primates. J Neurosci 1990;10:2897–2902.
  55. Simic G, Kostovic I, Winblad B, Bogdanovic N: Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer’s disease. J Comp Neurol 1997;379:482–494.
  56. West MJ, Coleman PD, Flood DG, Troncoso JC: Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer’s disease. Lancet 1994;344:769–772.
  57. West MJ, Kawas CH, Martin LJ, Troncoso JC: The CA1 region of the human hippocampus is a hot spot in Alzheimer’s disease. Ann NY Acad Sci 2000;908:255–259.
  58. Sapolsky RM, Krey LC, McEwen BS: The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr Rev 1986;7:284–301.
  59. de Leon MJ, McRae T, Tsai JR, George AE, Marcus DL, Freedman M, Wolf AP, McEwen B: Abnormal cortisol response in Alzheimer’s disease linked to hippocampal atrophy. Lancet 1988;ii:391–392.

    External Resources

  60. Pruessner JC, Lord C, Meaney M, Lupien S: Effects of self-esteem on age-related changes in cognition and the regulation of the hypothalamic-pituitary-adrenal axis. Ann NY Acad Sci 2004;1032:186–190.
  61. Clow A, Thorn L, Evans P, Hucklebridge F: The awakening cortisol response: methodological issues and significance. Stress 2004;7:29–37.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50